BACKGROUND: Because activation of T cells is associated with human immunodeficiency virus (HIV) pathogenesis, CD4 and CD8 activation levels in patients coinfected with HIV and hepatitis C virus (HCV) may explain conflicting reports regarding effects of HCV on HIV disease progression. METHODS: Kaplan-Meier and multivariate Cox regression models were used to study the risk of incident clinical AIDS and AIDS-related deaths among 813 HCV-negative women with HIV infection, 87 HCV-positive nonviremic women with HIV coinfection, and 407 HCV-positive viremic women with HIV coinfection (median follow-up time, 5.2 years). For 592 women, the percentages of activated CD4 and CD8 T cells expressing HLA-DR (DR) and/or CD38 were evaluated. RESULTS: HCV-positive viremic women had a statistically significantly higher percentage of activated CD8 T cells (P < .001) and a statistically significantly higher incidence of AIDS compared with HCV-negative women (P < .001 [log-rank test]). The AIDS risk was greater among HCV-positive viremic women in the highest tertile compared with the lowest tertile (>43% vs <26%) of CD8(+)CD38(+)DR(+) T cells (hazard ratio, 2.94 [95% confidence interval, 1.50-5.77]; P = .001). This difference was not observed in the HCV-negative women (hazard ratio, 1.87 [95% confidence interval, 0.80-4.35]; P = .16). In contrast, CD4 activation predicted AIDS in both groups similarly. Increased percentages of CD8(+)CD38(-)DR(+), CD4(+)CD38(-)DR(-), and CD8(+)CD38(-)DR(-) T cells were associated with a >60% decreased risk of AIDS for HCV-positive viremic women and HCV-negative women. CONCLUSION: HCV-positive viremic women with HIV coinfection who have high levels of T cell activation may have increased risk of AIDS. Earlier treatment of HIV and HCV infection may be beneficial.
BACKGROUND: Because activation of T cells is associated with human immunodeficiency virus (HIV) pathogenesis, CD4 and CD8 activation levels in patients coinfected with HIV and hepatitis C virus (HCV) may explain conflicting reports regarding effects of HCV on HIV disease progression. METHODS: Kaplan-Meier and multivariate Cox regression models were used to study the risk of incident clinical AIDS and AIDS-related deaths among 813 HCV-negative women with HIV infection, 87 HCV-positive nonviremic women with HIV coinfection, and 407 HCV-positive viremic women with HIV coinfection (median follow-up time, 5.2 years). For 592 women, the percentages of activated CD4 and CD8 T cells expressing HLA-DR (DR) and/or CD38 were evaluated. RESULTS:HCV-positive viremic women had a statistically significantly higher percentage of activated CD8 T cells (P < .001) and a statistically significantly higher incidence of AIDS compared with HCV-negative women (P < .001 [log-rank test]). The AIDS risk was greater among HCV-positive viremic women in the highest tertile compared with the lowest tertile (>43% vs <26%) of CD8(+)CD38(+)DR(+) T cells (hazard ratio, 2.94 [95% confidence interval, 1.50-5.77]; P = .001). This difference was not observed in the HCV-negative women (hazard ratio, 1.87 [95% confidence interval, 0.80-4.35]; P = .16). In contrast, CD4 activation predicted AIDS in both groups similarly. Increased percentages of CD8(+)CD38(-)DR(+), CD4(+)CD38(-)DR(-), and CD8(+)CD38(-)DR(-) T cells were associated with a >60% decreased risk of AIDS for HCV-positive viremic women and HCV-negative women. CONCLUSION:HCV-positive viremic women with HIV coinfection who have high levels of T cell activation may have increased risk of AIDS. Earlier treatment of HIV and HCV infection may be beneficial.
Authors: G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti Journal: Lancet Date: 2000-11-25 Impact factor: 79.321
Authors: E S Daar; H Lynn; S Donfield; E Gomperts; S J O'Brien; M W Hilgartner; W K Hoots; D Chernoff; S Arkin; W Y Wong; C A Winkler Journal: J Infect Dis Date: 2001-01-12 Impact factor: 5.226
Authors: Lena Al-Harthi; John Voris; Wenbo Du; David Wright; Marek Nowicki; Toni Frederick; Alan Landay; Andrea Kovacs Journal: J Infect Dis Date: 2006-03-17 Impact factor: 5.226
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Alan Landay; Lorie Benning; James Bremer; Barbara Weiser; Harold Burger; Marek Nowicki; Andrea Kovacs Journal: J Infect Dis Date: 2003-07-01 Impact factor: 5.226
Authors: Raymond T Chung; Scott R Evans; Yijun Yang; Dickens Theodore; Hernan Valdez; Rebecca Clark; Cecilia Shikuma; Thomas Nevin; Kenneth E Sherman Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Helen M Chun; Mollie P Roediger; Katherine Huppler Hullsiek; Chloe L Thio; Brian K Agan; William P Bradley; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F Crum-Cianflone; Jason D Maguire; Michael L Landrum Journal: J Infect Dis Date: 2011-12-05 Impact factor: 5.226
Authors: George A Yendewa; Foday Sahr; Antonio Aguilera; Sulaiman Lakoh; Momodu Sesay; Gibrilla F Deen; Lucia Patiño; Eva Poveda; Robert A Salata Journal: Am J Trop Med Hyg Date: 2019-06 Impact factor: 2.345
Authors: Roksana Karim; Wendy J Mack; Naoko Kono; Phyllis C Tien; Kathryn Anastos; Jason Lazar; Mary Young; Seema Desai; Elizabeth T Golub; Robert C Kaplan; Howard N Hodis; Andrea Kovacs Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Susanna E Winston; Brian T Montague; Michael J Lopez; Allison Delong; Chloe Lemarchand; Armando Bedoya; Fizza S Gillani; Curt G Beckwith Journal: J Int Assoc Provid AIDS Care Date: 2012-09-28